Andrew Zelenetz, MD, PhD | Authors

Selective benefit in high-risk patients, but won’t alter clinical practice

September 01, 2008

The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.